Quest PharmaTech Inc
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Quest PharmaTech Inc (QPTFF) - Total Liabilities
Latest total liabilities as of October 2025: $894.51K USD
Based on the latest financial reports, Quest PharmaTech Inc (QPTFF) has total liabilities worth $894.51K USD as of October 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Quest PharmaTech Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Quest PharmaTech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Quest PharmaTech Inc Competitors by Total Liabilities
The table below lists competitors of Quest PharmaTech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Feishang Anthracite Resources Limited
PINK:FSHRF
|
USA | $4.69 Billion |
|
Ensign Group Inc
STU:EGB
|
Germany | €2.77 Billion |
|
FP Newspapers Inc
PINK:FPNUF
|
USA | $824.00K |
|
Ck Infra Holdings Ltd
LSE:CKI
|
UK | GBX29.39 Billion |
|
Metrospaces Inc
PINK:MSPC
|
USA | $15.52 Million |
|
Ricky Putra Globalindo Tbk
JK:RICY
|
Indonesia | Rp1.59 Trillion |
|
Integrated Media Technology Ltd
NASDAQ:IMTE
|
USA | $16.66 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Quest PharmaTech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quest PharmaTech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quest PharmaTech Inc (2014–2025)
The table below shows the annual total liabilities of Quest PharmaTech Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | $1.17 Million | -11.67% |
| 2024-01-31 | $1.32 Million | +19.56% |
| 2023-01-31 | $1.11 Million | +77.71% |
| 2022-01-31 | $622.60K | +59.87% |
| 2021-01-31 | $389.44K | -96.87% |
| 2020-01-31 | $12.44 Million | +22.65% |
| 2019-01-31 | $10.14 Million | +1.95% |
| 2018-01-31 | $9.95 Million | +1256.57% |
| 2017-01-31 | $733.49K | -94.49% |
| 2016-01-31 | $13.30 Million | +227.17% |
| 2015-01-31 | $4.07 Million | +22.68% |
| 2014-01-31 | $3.31 Million | -- |